Having first achieved FDA approval in 2019, Oculogica’s EyeBOX remains the “only FDA-cleared and Health Canada registered diagnostic aid for concussion that does not require a pre-injury baseline test.” The new FDA label allows providers to use the EyeBOX to monitor a patient’s recovery over time by comparing the patient’s recovery to normative data.

A study found that an athlete’s symptom report is more accurate for concussion diagnosis than the Standardized Assessment of Concussion (SAC), a cognitive evaluation commonly used as part of the Sports Concussion Assessment Tool (SCAT).

In a recent study, Lily Li-Wen Wang et al. found that macrophage-adhering GLAMs can be used to identify the presence of mild traumatic brain injuries (mTBIs) that do not show up on standard MRI brain scans.

A recent study reported results on a handheld device, tested on a pig model, that can scan the retina of the eye to detect biochemical markers produced by the brain immediately after mild traumatic brain injury (mTBI).

Recent findings from a study published in American Journal of Physical Medicine and Rehabilitation revealed that using a speech-language pathology screening checklist may prove beneficial in predicting the need for a speech-language pathology referral for pediatric concussions.

Results from a recent study published in the Clinical Journal of Sports Medicine indicated that youth with exercise-induced vision dysfunction following sport-related concussion were at “a 3-folder greater risk” of developing persistent post-concussive symptoms (PPCS) compared to those without exercise-induced vision dysfunction.

Neurologists are frequently the providers tasked with making a differential diagnosis for patients with concussions and those with persistent post-concussive symptoms (PPCS). Leaders of the concussion field, including Dr. John Leddy and Concussion Alliance Advisory Board Member Dr. Barry Willer, have written a review, Clinical Assessment of Concussion and Persistent Post-Concussive Symptoms for Neurologists.